Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Adopts Definiens Biomarker Analysis Platform

NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

"VeriTrova accelerates clinical trials through remote uploading and viewing of digitized [immunohistochemistry] images from wet-lab partners and CROs to the cloud, where the images are analyzed," Thomas Colarusso, vice president of business development and strategy at Definiens, said in a statement.

Andrew Dorner, Takeda's vice president and global head of translational medicine, added that Definiens' system "will improve the timelines and quality of our image analysis for clinical biomarkers." 

Definiens said the real-time analysis provided by VeriTrova can help Takeda reduce normal processes from months to weeks, and can provide more automated and standardized image analysis readouts. 

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.